ONCAlert | 2018 ASCO Annual Meeting

A Biomarker Development Trial of Satraplatin in Patients With mCRPC

William K. Oh, MD
Published Online: 9:43 PM, Fri January 31, 2014
William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Clinical Pearls

  • Satraplatin is a next-generation chemotherapy drug that will not move forward in development
  • It is known that there is a subset of patients with advanced CRPC that respond to platinum chemotherapy
  • Blood- and tissue-based biomarkers are in development to predict the subset of patients that will respond

<<< Back to the GU 2014 conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.